Primary stent implantation for acute myocardial infarction during pregnancy: use of abciximab, ticlopidine, and aspirin

Cathet Cardiovasc Diagn. 1998 Nov;45(3):275-9. doi: 10.1002/(sici)1097-0304(199811)45:3<275::aid-ccd13>3.0.co;2-q.

Abstract

Recent evidence suggests that coronary stenting and the use of antiplatelet agents during coronary interventions will improve the outcome of patients with acute myocardial infarction (AMI). We describe the management of AMI in a 30-year-old woman, 38 weeks pregnant, with primary stenting and antiplatelet agents.

Publication types

  • Case Reports

MeSH terms

  • Abciximab
  • Adult
  • Antibodies, Monoclonal / therapeutic use
  • Aspirin / therapeutic use
  • Blood Vessel Prosthesis Implantation*
  • Coronary Angiography
  • Drug Therapy, Combination
  • Electrocardiography
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulin Fab Fragments / therapeutic use
  • Infant, Newborn
  • Male
  • Myocardial Infarction / diagnosis
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / surgery*
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Pregnancy
  • Pregnancy Complications, Cardiovascular*
  • Stents*
  • Ticlopidine / administration & dosage
  • Ticlopidine / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Ticlopidine
  • Aspirin
  • Abciximab